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We isolated a neurotoxin-specific monoclonal antibody (Mab) which is capable of recognizing and neutraliz- 
ing all short-chain toxin variants that have been tested, including those with widely divergent sequences. 
The epitope incorporates the three invariant residues Lys-27, Trp-29 and Lys-47 which form part of the 
site by which the toxins bind to the nicotinic acetylcholine receptor. To our knowledge, this is the first Mab 
which possesses the universal capacity of neutralizing all natural variants of a toxic protein. 
Monoclonal antibody Toxin Acetylcholine receptor 
1. INTRODUCTION 
Antibodies are capable of neutralizing the 
pathogenic action of a wide range of agents such as 
viruses, bacteria and toxins. This is achieved by 
binding to critical epitopes [ 1,2]. In practice, how- 
ever, the therapeutical importance of such proper- 
ties is often limited. Amino acid substitutions at 
the periphery of proteins generate interspecies anti- 
genie variations [3] and as a result antibodies 
raised against a given pathogenic agent often fail 
to recognize, and therefore to neutralize, a mutant 
or a variant. However, areas exist that are not or 
much less subject to such substitutions, for in- 
stance, the regions responsible for the common 
specific biological function. In principle, anti- 
bodies which are directed against such regions 
should be well-suited for a universal immuno- 
logical therapy. 
Snake bites are an important medical problem in 
many parts of the world [4]. Poisoning by Elapidae 
and Hydrophidae is often due to the neurotoxins 
that are present in their venoms [5]. These 
+ To whom correspondence should be addressed 
molecules hare the property of blocking the nerve- 
muscle transmission by binding to the nicotinic 
receptor of acetylcholine (AcChR) [5]. Due to a 
high level of interspecies antigenic variability, no 
universal antivenom is available against these 
molecules as yet. This paper reports for the first 
time the preparation and characterization of a 
monoclonal immunoglobulin which recognizes the 
AcChR-binding site of neurotoxins. This site con- 
stitutes the only conserved area shared by all 
variants isolated from the venoms of sea-snakes 
and land snakes (cobras and mambas). According- 
ly, the immunoglobulin is capable of inhibiting the 
binding to AcChR of all tested short-chain 
variants. 
2. MATERIALS AND METHODS 
Toxin LY was purified from Naja nigricollis 
venom (Pasteur Institute, Paris) as described [6]. 
Erabutoxins b and c from Laticauda semifasciata 
were kindly given to us by Professor N. Tamiya 
(Sendai, Japan). Toxins I and III from the venom 
of N. mossambica mossambica as well as 1251- 
labelled toxin I were kindly provided by Dr P. 
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Bougis (Marseille, France). Cobrotoxin from the 
venom of N. naja atra was generously donated by 
Professor K. Hayashi (Kyoto, Japan). ‘H-labelled 
toxin cy was prepared according to [7]. Poly- 
(ethylene glycol) (PEG), A4,6000, was from BDH 
(Poole, England). Lumagel and Lipoluma were 
obtained from Lumac, France. 
Cobrotoxin and erabutoxin b (10e4 M in 1 M 
phosphate buffer, pH 9) were iodinated with rz51 
using the chloramine T procedure [8]. The radio- 
immunoassays were performed by using PEG at a 
final concentration of 12.5% to precipitate the 
antigen-antibody complexes. The culture super- 
natants or ascitic fluids (0.1 ml) were incubated at 
room temperature for 2 h and then 4°C overnight 
with 0.1 ml (2 nM) of 3H-labelled toxin cy 
(30 Ci/mmol) in 0.05 M phosphate buffer and 
0.45% NaCl, pH 7. Normal horse serum 
(0.025 ml) and PEG (0.5 ml) were added to the 
solution. After centrifugation (Sorvall HS4 rotor, 
3000 rpm, 4”C, 30 min) the pellets were dissolved 
in 0.75 ml of 0.05 M NaOH and 10 ml Lumagel 
solution, and the radioactivity counted by using an 
Intertechnique counter. The background was less 
than 6% of the total radioactivity. Neutralization 
experiments were done under in vitro conditions. 
AcChR, prepared from electric organs from 
Torpedo marmorata according to [9], was in- 
cubated overnight at 4°C in the presence of radio- 
active toxins (protein concentrations are indicated 
in table 2) with various amounts of antibody in 
1.5 ml Ringer buffer. The mixtures were filtered 
through two Millipore filters (HAWP, 0.45 pm) 
which were washed with 30 ml of 4°C Ringer solu- 
tion. The dried filters were counted in 10 ml 
Lipoluma. Immunisation of Balb/c mice with tox- 
in was achieved according to [lo]. Fusion ex- 
periments were performed according to [I l] 
between myeloma cells (NS 63) and spleen cells 
from the hyperimmunized Balb/c mice. 
3. RESULTS AND DISCUSSION 
Short-chain neurotoxins constitute a large fami- 
ly of structurally and functionally homologous 
proteins, the polypeptide chains (60-62 residues) 
of which differ in sequence (review [12]). To iden- 
tify monoclonal antibodies that recognize con- 
served areas we screened antibody-secreting hybrid 
cells with two widely divergent short-chain neuro- 
toxins. These are toxin (Y from the land snake N. 
nigricollis [13] which was the original immunogen 
and erabutoxin b from the sea-snake L. semi- 
fasciata [14]. The toxins differ by 17 amino acid 
residues and share little cross-reactivity toward 
conventional antisera [2,15]. Fifteen fusion ex- 
periments [ll] were performed between myeloma 
cells (NS 63) and spleen cells from hyperimmu- 
nized Balb/c mice. On average, each fusion experi- 
ment led to hybrid growth in approx. 65 out of 70 
wells containing the selective HAT medium. Four 
hybrids produced antibodies that reacted with 3H- 
labelled toxin but not with 1251-labelled rabutoxin 
b and one produced an antibody which reacted 
with both radioactive toxins. This cell line was 
propagated intraperitoneally in mice and gave rise 
to an Ig2a immunoglobulin, designated as MG2-3. 
The binding of 3H-labelled toxin CY (30 Ci/mmol) 
to M&2-3 is saturable and highly specific. Scat- 
chard analysis of the binding data gave an 
equilibrium dissociation constant (&) of 9 nM. 
We examined the binding capacity for lv@2-3 of 
seven homologous toxins selected for their widely 
divergent sequences [12,16] and for their weak 
cross-reactivities toward polyclonal antibodies 
[2,15]. As shown in table 1, all toxins compete with 
3H-labelled toxin a for binding to the monoclonal 
Table 1 
Relative affinities of various homologous toxins toward 
MG2-3 
Homologous short-chain neurotoxins Apparent 
dissociation 
constants 
for McY2-3 
(Kdr nM) 
Naja nigricollis toxin cy 9 
Laticauda semifnsciata erabutoxin b 2 
Laticauda semifasciata erabutoxin c 2 
Laticauda colubrina toxin d 12 
Naja mossambica mossambica toxin I 138 
Naja mossambica mossambica toxin II! 1050 
Naja naja atra cobrotoxin 1500 
Kd values were calculated according to Ishikawa et al. 
[17] from competition experiments performed with ‘H- 
labelled toxin LY (2 nM, 20 Ci/mmol) and McY2-3 
(15 nM). Incubation times were 1 h at room tempera- 
ture, followed by 24 h at 4°C. Toxin-antibody com- 
plexes were precipitated by poly(ethylene glycol) [lo] 
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antibody with affinity constants ranging between 
2 nM and 1.5 pM. The antibody clearly possesses 
the capacity for neutralizing any of the toxins. This 
was demonstrated in vitro by monitoring the bind- 
ing inhibition to AcChR of four labelled toxins 
selected for their widely divergent affinities for 
MZ2-3 (table 1). Since the affinities of the toxins 
for AcChR are very similar (unpublished) it is clear 
(table 2) that the inhibition capacity of MG2-3 
follows the order erabutoxin b > toxin cr > toxin 
I > cobrotoxin. Clearly, neutralization efficiency 
of M&2-3 correlates with the binding affinities for 
the toxins. 
To delineate the epitope recognized by MZ2-3 
we prepared a number of derivatives of both toxin 
a! and erabutoxin b which were chemically 
modified at a single amino acid residue. Five toxin 
a derivatives monoa~etylated at the terminal 
amino group, Lys 15, 27, 47 and 51 together with 
a tryptophan derivatized toxin a! have all been 
shown to possess a spatial structure similar to that 
of the unmodified toxin [ 191. The relative affinities 
of MG2-3 for these derivatized toxins are presented 
in table 3. Acetylations at the NHz-terminal group, 
Table 2 
Neutralization in vitro of various short-chain neurotox- 
ins by MG2-3 
Receptor Labelied Concen- 
concen- toxin tration of 
tration concen- MG2-3 at 
(nM) tration 50% in- 
(nM) hibition 
GM) 
(1) (2) (3) 
‘2SI-labelh!d erabutoxin b 0.3 1.1 0.013 
%I-labelled toxin 1y 0.9 1.8 0.250 
‘251-labelIed toxin I 0.1 0.3 1.6 
‘2’I-labelled cobrotoxin 0.1 0.1 12 
AcChR (column 1) was incubated overnight with the 
radioactive toxins (column 2) in the presence of various 
amounts of antibody. The concentration of antibody 
which inhibits 50% of the binding of each toxin to 
AcChR is indicated in column 3. Specific activities of 
3W-labelled toxin ty, 1251-labelled erabutoxin b, ‘*‘I- 
labelled toxin I (kindly provided by P. Bougis) and ‘251- 
labelled cobrotoxin were equal to 30, 120, 670 and 
450 Wmmol, respectively. The values are means of 
four independent determinations 
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Table 3 
Relative affinities of various monoderivatiz~d toxins 
toward h&%2-3 or AcChR 
Derivatives of two short-chain Apparent dissocia- 
neurotoxins tion constants (&) 
Mg2-3 AcChR 
(nM) (PM) 
Naja nigricollis toxin a! 9 20(b) 
(1-N*-acetylleucine) toxin cy 9 30(b) 
(15-N”-acetyllysine) toxin cy 5 90(b) 
(27-N”-acetyllysine) toxin cy 61 2%(b) 
(47-No-acetyliysine) toxin cy 85 520(b) 
(5 l-No-acetyliysine) toxin ty 5 90(b) 
(29-Cz-NPS tryptophan) toxin ty (a) 172 590(b) 
Laiicauda semifasciata erabutoxin b 2 120 
(15-Nf-acetyllysine) erabutoxin b 2 nd 
(27-No-acetylIysine) rabutoxin b 15 nd 
(47-No-acetyllysine) erabutoxin b 60 4(mc) 
@I-N”-acetyllysine) erabutoxin b 2 nd 
Kd values were calculated as indicated in table 1. (a) NPS 
indicates that a nitrophenyl group has been incorporated 
on the Cz position of the indoie side chain by a thioether 
bond. (b) After Faure et al. 1191. (c) After Ishikawa et 
al. 1171 
or at Lys 15 or 51, do not alter the affinity from 
that of the native toxin while acetylations at posi- 
tions 27 and 47, or Trp 29 modification induce a 
decrease in affinity by factors of 7, 9 and 20, 
respectively. Parallel studies with monoacetyfated 
derivatives of erabutoxin b [20] indicate that Lys 
27 and 47 of erabutoxin b are involved in the 
epitope whereas residues 15 and 51 are not. Fur- 
thermore, Lys 51 of erabutoxin b can be 
substituted by an asparagine (erabutoxin c [ 11 J), 
without affecting the M~2-3-binding properties. 
These observations lead to the conclusion that the 
sites by which neurotoxins bind to McU2-3 contain 
at least the two amino groups at position 27 and 47 
and the indole group at position 29. 
The site by which neurotoxins bind to AcChR 
has been previously elucidated [12,19,211. It com- 
prises invariant residues which are mainly 
distributed on the second and third loops of the 
toxins and are orientated to the same side of the ,& 
pleated sheet formed by three long and adjacent 
loops. The three antigenically critical residues 27, 
29 and 47 form part of the A~ChR-binding site 
(fig.1). This is iltustrated in table 3 where it is 
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Fig. 1. Amino acid residues incorporated in the epitope 
recognized by Mcr2-3. The spatial structure is based on 
X-ray data of erabutoxin b [23,24] according to Kimball 
et al. [22]. The three underlined residues at position 27, 
29 and 47 are common to both the epitope and the 
AcChR-binding site. The residues incorporated in the 
AcChR-binding site [12,19,21] are mainly localized on 
the shaded loops II and III. 
reported that their selective derivatizations always 
induce a decrease in toxin-binding affinity for 
AcChR [ 191. It is clear therefore that the toxin sites 
recognized by AcChR and MG2-3 overlap. 
The AcChR-binding site and the epitope, how- 
ever, are not identical in the strict sense. This is in- 
dicated, in particular, by the large affinity 
differences for MG2-3 and AcChR of toxin a, or 
erabutoxin b (table 3) and by the lack of cross- 
reactivity (not shown) of long-chain neurotoxins 
[25] which are high-affinity competitors of short- 
chain neurotoxins for AcChR [12,17]. To clarify 
the differences between the two sites we delineated 
more precisely the epitope by determining the cor- 
relation of cross-reactivity with the seven 
homologous toxins listed in table 1 and amino acid 
differences in the primary structures [12,16]. This 
analysis which will be published in detail elsewhere 
indicates the critical role of residues 7, 10 and 11 
which all occupy positions on the first loop of the 
toxins and are orientated to the same side of the 
sheet as residues 27, 29 and 47. We conclude, 
therefore, that the binding sites of X2-3 and 
AcChR are located on the same face of the&sheet, 
overlap within loops II and III and differ from 
each other in that the epitope extends to the first 
loop of the molecule. 
The monoclonal antibody described here 
recognizes part of the functional site of the short- 
chain neurotoxins and possesses accordingly the 
capacity for both recognizing and neutralizing all 
homologous molecules that have been tested. This 
property is of potential importance since it should 
allow the detection and/or neutralization of such a 
molecule without knowledge of its actual origin, 
i.e. the nature of snake responsible for the bite. 
Four different toxin classes are responsible for the 
lethal effect of most Elapidae and Hydrophidae 
venoms [5]. These are short-chain neurotoxins, 
long-chain neurotoxins, cardiotoxins and phos- 
pholipases, all of which present extensive inter- 
species antigenic variations (review 121). In 
principle, therefore, a cocktail of four antibodies 
each directed to the conserved area of one of the 
four specific toxins should be sufficient for de- 
tecting and/or neutralizing any venom of Elapidae 
or Hydrophidae. MG2-3 constitutes the first 
monoclonal immunoglobulin of this type. 
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